454 related articles for article (PubMed ID: 19718025)
1. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Prickett TD; Agrawal NS; Wei X; Yates KE; Lin JC; Wunderlich JR; Cronin JC; Cruz P; Rosenberg SA; Samuels Y
Nat Genet; 2009 Oct; 41(10):1127-32. PubMed ID: 19718025
[TBL] [Abstract][Full Text] [Related]
2. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
3. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
4. A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U; Samuels Y
Cell Cycle; 2010 Apr; 9(8):1487-503. PubMed ID: 20404484
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.
Mirkina I; Hadzijusufovic E; Krepler C; Mikula M; Mechtcheriakova D; Strommer S; Stella A; Jensen-Jarolim E; Höller C; Wacheck V; Pehamberger H; Valent P
PLoS One; 2014; 9(1):e84417. PubMed ID: 24489649
[TBL] [Abstract][Full Text] [Related]
6. The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
Zhou QM; Li W; Guan YX; Zhang X; Chen XC; Ding Y; Wen XZ; Peng RQ; Yan SM; Zhang XS
Chin J Cancer; 2013 Jul; 32(7):410-4. PubMed ID: 23237222
[TBL] [Abstract][Full Text] [Related]
7. Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.
Cullum RL; Lucas LM; Senfeld JI; Piazza JT; Neel LT; Whig K; Zhai L; Harris MH; Rael CC; Taylor DC; Cook LJ; Kaufmann DP; Mill CP; Jacobi MA; Smith FT; Suto M; Bostwick R; Gupta RB; David AE; Riese Ii DJ
PLoS One; 2020; 15(12):e0243901. PubMed ID: 33378376
[TBL] [Abstract][Full Text] [Related]
8. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
Settleman J
Cancer Cell; 2009 Oct; 16(4):278-9. PubMed ID: 19800573
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of the ERBB4 kinase domain in human cancers.
Soung YH; Lee JW; Kim SY; Wang YP; Jo KH; Moon SW; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2006 Mar; 118(6):1426-9. PubMed ID: 16187281
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
11. Mutations in ERBB4 may have a minor role in melanoma pathogenesis.
Manca A; Lissia A; Cossu A; Rubino C; Ascierto PA; Stanganelli I; Palmieri G
J Invest Dermatol; 2013 Jun; 133(6):1685-7. PubMed ID: 23340734
[No Abstract] [Full Text] [Related]
12. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.
Tvorogov D; Sundvall M; Kurppa K; Hollmén M; Repo S; Johnson MS; Elenius K
J Biol Chem; 2009 Feb; 284(9):5582-91. PubMed ID: 19098003
[TBL] [Abstract][Full Text] [Related]
14. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
15. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
16. Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma.
Yue L; Huang ZM; Fong S; Leong S; Jakowatz JG; Charruyer-Reinwald A; Wei M; Ghadially R
Melanoma Res; 2015 Apr; 25(2):138-48. PubMed ID: 25643237
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
[TBL] [Abstract][Full Text] [Related]
18. CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins.
Riecken LB; Zoch A; Wiehl U; Reichert S; Scholl I; Cui Y; Ziemer M; Anderegg U; Hagel C; Morrison H
Oncotarget; 2016 Nov; 7(48):78242-78254. PubMed ID: 27793041
[TBL] [Abstract][Full Text] [Related]
19. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
Chen ZH; Yu YP; Tao J; Liu S; Tseng G; Nalesnik M; Hamilton R; Bhargava R; Nelson JB; Pennathur A; Monga SP; Luketich JD; Michalopoulos GK; Luo JH
Gastroenterology; 2017 Oct; 153(4):1120-1132.e15. PubMed ID: 28245430
[TBL] [Abstract][Full Text] [Related]
20. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
Niu HT; Zhou QM; Wang F; Shao Q; Guan YX; Wen XZ; Chen LZ; Feng QS; Li W; Zeng YX; Zhang XS
Pigment Cell Melanoma Res; 2013 Sep; 26(5):646-53. PubMed ID: 23751074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
